inflammatory diseases

News

NHS saving £300m with Humira biosimilar deal

The NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of AbbVie’s Humira inflammatory diseases drug.

News

Samsung Bioepis' Humira biosimilar launches in EU

Samsung Bioepis has become the latest biosimilars company to confirm it has launched a cheaper near-copy of AbbVie’s Humira inflammatory diseases blockbuster, after its European patent expi

News

Billions up for grabs as EU patent on AbbVie's Humira expire...

The patent for Humira, the world’s bestselling drug, expires in Europe today – opening the door for a host of cheaper biosimilars to hit the market.

News

Sandoz free to launch Humira biosimilar following AbbVie dea...

Novartis’ generics and biosimilars arm, Sandoz, has confirmed it is to launch its biosimilar of AbbVie’s Humira (adalimumab) in Europe this year after the two companies settled intellectual

News

Janssen J&J Johnson and Johnson pharmaceutical companies

New data sets up potential new gastro use for J&J's Stelara

Janssen’s Stelara has shown positive results in an ulcerative colitis (UC) trial, setting up a potential new indication for the inflammatory diseases drug.

News

Merck & Co signs biosimilars deal for US veterans

Merck & Co has signed a deal with the US Department of Veterans Affairs (VA) for its inflammatory diseases biosimilar, Renflexis, so that veterans’ care can be improved.

NHS saving £300m with Humira biosimilar deal

Samsung Bioepis' Humira biosimilar launches in EU

Billions up for grabs as EU patent on AbbVie's Humira expire...

Sandoz free to launch Humira biosimilar following AbbVie dea...

New data sets up potential new gastro use for J&J's Stelara

Merck & Co signs biosimilars deal for US veterans

Protego's $130m for amyloidosis drug, and other financings

How to meet your physicians where they are online

inflammatory diseases

Editor's Picks